Outcomes-Based Contract By Harvard Pilgrim For Testing Could Be Model For Pharma
Prenatal testing services provider IIlumina commits to fund study on whether cost of expanding use of test is offset by reduction in spending on traditional screening practices.
You may also be interested in...
Novel reimbursement scheme allowing payers to spread out the cost of an expensive gene therapy over time may get test drive with Spark's Luxturna before being used for big-market treatments for hemophilia.
US FDA's accelerated approval pathway is more reliable and has better validated biomarkers than a decade ago, commissioner says, arguing coverage limits on AA products are not in the interest of public health.
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.